EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer

Yi Cao, Xiaojiao Ge, Xueli Zhu, Yingying Han, Pin Wang, Ozioma Udochukwu Akakuru, Aiguo Wu iD, Juan Li iD

Advanced Science · 2023

DOI: 10.1002/advs.202300545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Yi Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, CAS Key Laboratory of Ma…. Hauptthemen laut MEDLINE: Prodrugs, Triple Negative Breast Neoplasms, Neuropeptides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Zhejiang Province, National Natural Science Foundation of China, Science & Technology Bureau of Ningbo City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) has the worst prognosis among all breast cancer subtypes due to lack of specific target sites and effective treatments. Herein, a transformable prodrug (DOX‐P18) based on neuropeptide Y analogue with tumor microenvironment responsiveness is developed for TNBC treatment. The prodrug DOX‐P18 can achieve reversible morphological transformation between monomers and nanoparticles through the manipulation of protonation degree in different environments. It can self‐assemble into nanoparticles to enhance the circulation stability and drug delivery efficiency in the physiological environment while transforming from nanoparticles to monomers and being endocytosed into the breast cancer cells in the acidic tumor microenvironment. Further, the DOX‐P18 can precisely be enriched in the mitochondria, and efficiently activated by matrix metalloproteinases. Then, the cytotoxic fragment (DOX‐P3) can subsequently be diffused into the nucleus, generating a sustained cell toxicity effect. In the meanwhile, the hydrolysate residue P15 can assemble into nanofibers to construct nest‐like barriers for the metastasis inhibition of cancer cells. After intravenous injection, the transformable prodrug DOX‐P18 demonstrated superior tumor growth and metastasis suppression with much better biocompatibility and improved biodistribution compared to free DOX. As a novel tumor microenvironment‐responsive transformable prodrug with diversified biological functions, DOX‐P18 shows great potential in smart chemotherapeutics discovery for TBNC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsTriple Negative Breast NeoplasmsNeuropeptidesHumansDoxorubicinTumor MicroenvironmentTissue Distribution

Stichwörter der Autor:innen

mitochondria targetabilityneuropeptidetransformable prodrugtriple-negative breast cancertumor growth and metastasis

Substanzen

ProdrugsDoxorubicinNeuropeptides

Autor:innen und Institutionen

  • Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, CAS Key Laboratory of Magnetic Materials and Devices, Zhejiang Engineering Research Center for…
  • University of Chinese Academy of Sciences, 100049, Beijing, P. R. China.

ORCID-Profile: Aiguo Wu, Juan Li

Förderung

  • Key R&D Program of Zhejiang Province
  • National Natural Science Foundation of China
  • Science & Technology Bureau of Ningbo City
  • Excellent Member of Youth Innovation Promotion Association Foundation of CAS

Zitieren

APA

Cao, Y., Ge, X., Zhu, X., Han, Y., Wang, P., Akakuru, O. U., Wu, A., & Li, J. (2023). Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202300545

Vancouver

Cao Y, Ge X, Zhu X, Han Y, Wang P, Akakuru OU, et al. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer. Advanced Science. 2023. doi:10.1002/advs.202300545

BibTeX
@article{Cao2023,
  author = {Cao, Yi and Ge, Xiaojiao and Zhu, Xueli and Han, Yingying and Wang, Pin and Akakuru, Ozioma Udochukwu and Wu, Aiguo and Li, Juan},
  title = {Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer},
  journal = {Advanced Science},
  year = {2023},
  doi = {10.1002/advs.202300545}
}
Kostenlos starten →